Emerging biological agents for hepatitis C

Valentina Zuccaro, Paola Columpsi, Alice Apollinari, Paolo Sacchi, Marco Mussa, Andrea Schimmenti, Maria Grazia Lucà, Stefano Fagiuoli, Raffaele Bruno

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

ABSTRACT: Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic HCV infection. Despite current treatments are well tolerated with a high rate of sustained virological response (SVR), some medical needs remain. Nowadays there are a large number of approved medications for the treatment of HCV infection; nevertheless, new studies are conducted to find new agents and new combinations. Areas covered: A literature research of new antiviral compounds indicated for the treatment of HCV infection was achieved by an online search of medication undergoing development on Pubmed and clinicalTrials.gov clinical trials registry. We considered phase I/II studies and some randomized Phase III trials. Expert opinion: More knowledge about impact of HCV eradication on disease progression and more confidence regarding drug-drug interaction are needed. Furthermore, each treatment should be individualized targeting the patients needs with the aim not only to obtain viral suppression but also to stop progression of liver disease and HCV related conditions, and to improve patient health status.

Original languageEnglish
Pages (from-to)219-224
Number of pages6
JournalExpert Opinion on Emerging Drugs
Volume21
Issue number2
DOIs
Publication statusPublished - Apr 2 2016

Fingerprint

Biological Factors
Hepatitis C
Antiviral Agents
Infection
Therapeutics
Expert Testimony
Drug Interactions
PubMed
Health Status
Registries
Disease Progression
Liver Diseases
Clinical Trials
Research
Pharmaceutical Preparations

Keywords

  • DAA’s
  • direct antiviral agents
  • HCV
  • therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging biological agents for hepatitis C. / Zuccaro, Valentina; Columpsi, Paola; Apollinari, Alice; Sacchi, Paolo; Mussa, Marco; Schimmenti, Andrea; Lucà, Maria Grazia; Fagiuoli, Stefano; Bruno, Raffaele.

In: Expert Opinion on Emerging Drugs, Vol. 21, No. 2, 02.04.2016, p. 219-224.

Research output: Contribution to journalReview article

Zuccaro, V, Columpsi, P, Apollinari, A, Sacchi, P, Mussa, M, Schimmenti, A, Lucà, MG, Fagiuoli, S & Bruno, R 2016, 'Emerging biological agents for hepatitis C', Expert Opinion on Emerging Drugs, vol. 21, no. 2, pp. 219-224. https://doi.org/10.1080/14728214.2016.1184645
Zuccaro V, Columpsi P, Apollinari A, Sacchi P, Mussa M, Schimmenti A et al. Emerging biological agents for hepatitis C. Expert Opinion on Emerging Drugs. 2016 Apr 2;21(2):219-224. https://doi.org/10.1080/14728214.2016.1184645
Zuccaro, Valentina ; Columpsi, Paola ; Apollinari, Alice ; Sacchi, Paolo ; Mussa, Marco ; Schimmenti, Andrea ; Lucà, Maria Grazia ; Fagiuoli, Stefano ; Bruno, Raffaele. / Emerging biological agents for hepatitis C. In: Expert Opinion on Emerging Drugs. 2016 ; Vol. 21, No. 2. pp. 219-224.
@article{f19d82d7cb5f432a884776483a39f6a1,
title = "Emerging biological agents for hepatitis C",
abstract = "ABSTRACT: Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic HCV infection. Despite current treatments are well tolerated with a high rate of sustained virological response (SVR), some medical needs remain. Nowadays there are a large number of approved medications for the treatment of HCV infection; nevertheless, new studies are conducted to find new agents and new combinations. Areas covered: A literature research of new antiviral compounds indicated for the treatment of HCV infection was achieved by an online search of medication undergoing development on Pubmed and clinicalTrials.gov clinical trials registry. We considered phase I/II studies and some randomized Phase III trials. Expert opinion: More knowledge about impact of HCV eradication on disease progression and more confidence regarding drug-drug interaction are needed. Furthermore, each treatment should be individualized targeting the patients needs with the aim not only to obtain viral suppression but also to stop progression of liver disease and HCV related conditions, and to improve patient health status.",
keywords = "DAA’s, direct antiviral agents, HCV, therapy",
author = "Valentina Zuccaro and Paola Columpsi and Alice Apollinari and Paolo Sacchi and Marco Mussa and Andrea Schimmenti and Luc{\`a}, {Maria Grazia} and Stefano Fagiuoli and Raffaele Bruno",
year = "2016",
month = "4",
day = "2",
doi = "10.1080/14728214.2016.1184645",
language = "English",
volume = "21",
pages = "219--224",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Emerging biological agents for hepatitis C

AU - Zuccaro, Valentina

AU - Columpsi, Paola

AU - Apollinari, Alice

AU - Sacchi, Paolo

AU - Mussa, Marco

AU - Schimmenti, Andrea

AU - Lucà, Maria Grazia

AU - Fagiuoli, Stefano

AU - Bruno, Raffaele

PY - 2016/4/2

Y1 - 2016/4/2

N2 - ABSTRACT: Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic HCV infection. Despite current treatments are well tolerated with a high rate of sustained virological response (SVR), some medical needs remain. Nowadays there are a large number of approved medications for the treatment of HCV infection; nevertheless, new studies are conducted to find new agents and new combinations. Areas covered: A literature research of new antiviral compounds indicated for the treatment of HCV infection was achieved by an online search of medication undergoing development on Pubmed and clinicalTrials.gov clinical trials registry. We considered phase I/II studies and some randomized Phase III trials. Expert opinion: More knowledge about impact of HCV eradication on disease progression and more confidence regarding drug-drug interaction are needed. Furthermore, each treatment should be individualized targeting the patients needs with the aim not only to obtain viral suppression but also to stop progression of liver disease and HCV related conditions, and to improve patient health status.

AB - ABSTRACT: Introduction: New direct-acting antiviral agents have changed the landscape of treatment of chronic HCV infection. Despite current treatments are well tolerated with a high rate of sustained virological response (SVR), some medical needs remain. Nowadays there are a large number of approved medications for the treatment of HCV infection; nevertheless, new studies are conducted to find new agents and new combinations. Areas covered: A literature research of new antiviral compounds indicated for the treatment of HCV infection was achieved by an online search of medication undergoing development on Pubmed and clinicalTrials.gov clinical trials registry. We considered phase I/II studies and some randomized Phase III trials. Expert opinion: More knowledge about impact of HCV eradication on disease progression and more confidence regarding drug-drug interaction are needed. Furthermore, each treatment should be individualized targeting the patients needs with the aim not only to obtain viral suppression but also to stop progression of liver disease and HCV related conditions, and to improve patient health status.

KW - DAA’s

KW - direct antiviral agents

KW - HCV

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84975230829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975230829&partnerID=8YFLogxK

U2 - 10.1080/14728214.2016.1184645

DO - 10.1080/14728214.2016.1184645

M3 - Review article

AN - SCOPUS:84975230829

VL - 21

SP - 219

EP - 224

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -